Community Bank & Trust Waco Texas Has $446,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Community Bank & Trust Waco Texas lowered its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 2.9% in the third quarter, HoldingsChannel reports. The firm owned 5,719 shares of the company’s stock after selling 171 shares during the period. Community Bank & Trust Waco Texas’ holdings in AstraZeneca were worth $446,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its holdings in AstraZeneca by 17.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock worth $4,151,177,000 after acquiring an additional 9,002,450 shares during the last quarter. Swedbank AB bought a new stake in AstraZeneca during the 1st quarter worth about $186,127,000. Manning & Napier Advisors LLC bought a new stake in AstraZeneca during the 2nd quarter worth about $188,476,000. Hsbc Holdings PLC grew its holdings in AstraZeneca by 750.3% during the 2nd quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock worth $100,523,000 after acquiring an additional 1,132,362 shares during the last quarter. Finally, Farallon Capital Management LLC grew its holdings in AstraZeneca by 65.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock worth $187,934,000 after acquiring an additional 950,000 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZN stock opened at $65.19 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a market capitalization of $202.13 billion, a P/E ratio of 31.49, a price-to-earnings-growth ratio of 1.20 and a beta of 0.47. The company’s 50 day moving average price is $76.20 and its two-hundred day moving average price is $78.47.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. TD Cowen raised their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.